pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Demographic characteristics and migraine prophylactic drug utilization.

N Prophylactic utilization (%) p-Value
Total 534 234(43.8)
Age group <40 147(27.5) 71(48.3) 0.382
40-49 165(30.9) 72(43.6)
≥50 222(41.6) 91(41.0)
Sex Male 108(20.2) 41(38.0) 0.170
Female 426(79.8) 193(45.3)
Insurance NHI 514(96.3) 225(43.8) 0.914
MedAid/PVI 20(3.7) 9(45.0)
Migraine type Migraine without aura 202(37.8) 113(55.9) <0.001
Migraine with aura 40(7.5) 17(42.5)
Other migraine 292(54.7) 104(35.6)
Epilepsy No 508(95.1) 212(41.7) <0.001
Yes 26(4.9) 22(84.6)
Depressive disorders No 406(76.0) 152(37.4) <0.001
Yes 128(24.0) 82(64.1)
Insomnia No 464(86.9) 194(41.8) 0.016
Yes 70(13.1) 40(57.1)
Hypertension No 416(77.9) 178(42.8) 0.367
Yes 118(22.1) 56(47.5)
Diabetes mellitus No 466(87.3) 198(42.5) 0.105
Yes 68(12.7) 36(52.9)
Dyslipidemia No 337(63.1) 134(39.8) 0.013
Yes 197(36.9) 100(50.8)
Osteoarthritis No 374(70.0) 153(40.9) 0.038
Yes 160(30.0) 81(50.6)
Rheumatoid arthritis No 507(94.9) 222(43.8) 0.947
Yes 27(5.1) 12(44.4)
Asthma No 458(85.8) 194(42.4) 0.095
Yes 76(14.2) 40(52.6)
Thyroid gland disorders No 434(81.3) 190(43.8) 0.968
Yes 100(18.7) 44(44.0)

NHI, national health insurance; MedAid, medical aid; PVI, patriots & veterans insurance; COPD, chronic obstructive pulmonary disease

Korean J Clin Pharm 2021;31:35-43 https://doi.org/10.24304/kjcp.2021.31.1.35
© 2021 Korean J Clin Pharm